Apolo highlighted the positive topline results from the phase 3 EV-303 trial (NCT03924895) evaluating EV plus pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer.
Andrea B. Apolo, MD
Advertisement
Apolo is acting deputy chief of the Genitourinary Malignancies Branch of the National Cancer Institute Center for Cancer Research, head of the Genitourinary Malignancies Branch’s Bladder Cancer Section, and director of the Bladder Cancer and Genitourinary Tumors Multidisciplinary Clinic.
Articles by Andrea B. Apolo, MD
Apolo also discusses the potential role of ctDNA in the bladder cancer space.
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC.
Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
